comparemela.com

Page 7 - Jim Neal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New Executive Leadership Team Appointed to Accelerate XOMA s Differentiated Royalty Monetization Strategy Seite 1

04.01.2023 - Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) - XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced . Seite 1

XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset Being Developed by Organon

XOMA Corporation , a biotech royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of advancing novel therapeutic candidates aimed at improving human health,. | November 23, 2022

XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon

22.11.2022 - XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay Potential to earn $475 million in development, regulatory, and sales . Seite 1

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.